Commericalization

CSPC develops, produces and sells its own innovative drugs. Its growth has been sluggish over the past three years due to a slowdown for its finished drug business.

FAST NEWS: CSPC Pharma’s urticaria drug approved in China

The Latest: CSPC Pharmaceutical Group Ltd. (1093.HK) announced on Tuesday that its chronic spontaneous urticaria treatment, Omalizumab for Injection, has been approved for sale in China by the country’s National Medical Products Administration…
1093.HK

Recent Articles

RELATED ARTICLES

  1. Earnings blow for CSPC Pharma
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  2. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  3. Cancer drug maker Genfleet joins Hong Kong IPO influx
  4. Hengrui Pharma accelerates bid for global brand status
    600276.SHG
  5. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  6. Xuanzhu Biopharm set for spin-off in Hong Kong IPO
    0460.HK
  7. Innogen Pharma jostles for a slice of the weight-loss market
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva